SAN DIEGO, January 18, 2022--(BUSINESS WIRE)--PhenoVista Biosciences announced today that it has secured funding from BroadOak Capital Partners, a life science-focused investor. Since its founding in 2014, PhenoVista has democratized access to high-content analysis of physiologically relevant cell models. The investment will be used to develop new complex products, such as models of the blood-brain barrier and platforms for better understanding neurodegenerative diseases.
"The funding provided by our partners at BroadOak will enable us to accelerate our growth by continuing to invest in our passion - providing our clients with data from cutting-edge cell models not available from any other service provider," stated James G. Evans, CEO and co-founder of PhenoVista. "Most importantly, by increasing our resources, we can deliver impactful information to more clients faster than ever, increasing the value of our contribution to global health."
PhenoVista’s team is comprised of experts in diverse fields, such as imaging, assay development, high-throughput and high-content data analysis, microfluidics, machine learning and AI, and advanced cell culture, including primary cells, neurons, organoids, and spheroids. The team’s broad, deep, and versatile skillsets uniquely position the company to tackle challenges in all areas of biology, from immunology and fibrosis to neurodegenerative diseases.
PhenoVista has demonstrated its expertise and experience by successfully meeting the complex challenges of clients’ research projects, including developing assays for small and large biotechnology and pharmaceutical companies as well as government agencies. To date, they have developed over 100 different phenotypic assays through their flexible style of engagement with clients to meet their needs.
Demand from the drug-discovery industry for increasing quantities of bespoke services is accelerating growth opportunities for PhenoVista. With BroadOak’s funding, PhenoVista will continue to stay at the forefront of imaging and data-analysis methods and create new models of biological systems in growing fields of interest. These advancements will offer scientists new strategies for enhancing drug-discovery processes and gaining greater insights into biological phenomena, ultimately improving healthcare options for patients everywhere.
About PhenoVista Biosciences
PhenoVista Biosciences is a leading provider of customized, imaging-based, phenotypic assay services based in San Diego, California. PhenoVista has built a strong reputation globally on providing high-quality data with a collaborative, adaptable nature of engagement to biopharmaceutical clients that range from local start-ups to multi-national organizations. Their diverse repertoire includes working with primary cells, iPSC-derived neurons, and client-engineered lines in 2D, 3D, co-culture, and microfluidic systems to construct myriad functional, structural, and pre-clinical, therapeutic assays. For more information, visit www.phenovista.com.
About BroadOak Capital Partners
BroadOak Capital Partners, with headquarters in Washington, DC and San Francisco, is a life-sciences focused boutique financial institution that provides direct investment and investment banking services to companies in the research tools and consumables, diagnostics, biopharma services, and adjacent markets. BroadOak has led or participated in investments in more than 50 companies in their niche across multiple funds and investment vehicles. For more information, visit www.broadoak.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220118005244/en/